Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 526,156 shares, a growth of 160.9% from the January 15th total of 201,697 shares. Based on an average trading volume of 481,087 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.3% of the shares of the stock are sold short. Approximately 0.3% of the shares of the stock are sold short. Based on an average trading volume of 481,087 shares, the days-to-cover ratio is presently 1.1 days.

Institutional Investors Weigh In On Enlivex Therapeutics

Large investors have recently modified their holdings of the company. Citizens Financial Group Inc. RI purchased a new stake in shares of Enlivex Therapeutics during the 3rd quarter worth $241,000. Jane Street Group LLC raised its stake in Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares in the last quarter. Finally, Susquehanna International Group LLP purchased a new stake in Enlivex Therapeutics during the 3rd quarter worth about $57,000. 1.02% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. D. Boral Capital restated a “hold” rating on shares of Enlivex Therapeutics in a research report on Monday, November 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enlivex Therapeutics in a research note on Monday, December 29th. Wall Street Zen upgraded Enlivex Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, January 17th. Finally, HC Wainwright lifted their price objective on Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $13.00.

Enlivex Therapeutics Stock Performance

Shares of Enlivex Therapeutics stock traded down $0.02 during trading hours on Thursday, reaching $1.12. 156,060 shares of the company were exchanged, compared to its average volume of 450,553. The firm has a market cap of $265.87 million, a PE ratio of -2.04 and a beta of 1.63. The stock’s fifty day moving average is $0.95 and its 200 day moving average is $1.06. Enlivex Therapeutics has a 1 year low of $0.66 and a 1 year high of $2.10.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.03. Research analysts expect that Enlivex Therapeutics will post -0.7 earnings per share for the current year.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.